Literature DB >> 8536857

Down-regulation of expression and function of the rat liver Na+/bile acid cotransporter in extrahepatic cholestasis.

C Gartung1, M Ananthanarayanan, M A Rahman, S Schuele, S Nundy, C J Soroka, A Stolz, F J Suchy, J L Boyer.   

Abstract

BACKGROUND & AIMS: The molecular regulation of hepatic bile acid transporters during cholestasis is largely unknown. Cloning of complementary DNAs for the sinusoidal sodium-dependent taurocholate cotransporting polypeptide (ntcp), the cytosolic bile acid-binding protein 3 alpha-hydroxysteroid dehydrogenase (3 alpha-HSD), and a putative canalicular bile acid transporter Ca2+, Mg(2+)-ecto-adenosine triphosphatase, now facilitates such studies.
METHODS: Protein mass, steady-state messenger RNA (mRNA) levels, and gene transcription were assessed in rat livers after common bile duct ligation (CBDL) from 1-7 days, and taurocholate uptake was determined in isolated hepatocytes.
RESULTS: After CBDL, Na(+)-dependent taurocholate uptake (Vmax) declined by 70%. The levels of ntcp protein were reduced by more than 90%, and 3 alpha-HSD levels decreased by 66% by 7 days. Expression and canalicular localization of the ecto-adenosine triphosphatase remained unchanged. mRNA levels for both ntcp and 3 alpha-HSD diminished by about 60% 1 day after CBDL and remained unchanged up to 7 days. Transcriptional activity was decreased 1 day after CBDL only for ntcp.
CONCLUSIONS: Extrahepatic cholestasis results in rapid down-regulation of Na(+)-dependent taurocholate uptake, ntcp transcription, and posttranscriptional regulation of both ntcp and 3 alpha-HSD mRNA. This selective decline of ntcp may represent a protective feedback mechanism in cholestasis to diminish uptake of potentially hepatotoxic bile acids.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8536857     DOI: 10.1053/gast.1996.v110.pm8536857

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  36 in total

Review 1.  Hepatocellular transport proteins and their role in liver disease.

Authors:  C Stanca; D Jung; P J Meier; G A Kullak-Ublick
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

2.  Berberine-induced Inactivation of Signal Transducer and Activator of Transcription 5 Signaling Promotes Male-specific Expression of a Bile Acid Uptake Transporter.

Authors:  Pengli Bu; Yuan Le; Yue Zhang; Youcai Zhang; Xingguo Cheng
Journal:  J Biol Chem       Date:  2017-02-01       Impact factor: 5.157

Review 3.  Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity.

Authors:  Brandon Swift; Nathan D Pfeifer; Kim L R Brouwer
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

Review 4.  Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.

Authors:  Gustav Paumgartner
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

Review 5.  Bile secretion--models, mechanisms, and malfunctions. A perspective on the development of modern cellular and molecular concepts of bile secretion and cholestasis.

Authors:  J L Boyer
Journal:  J Gastroenterol       Date:  1996-06       Impact factor: 7.527

Review 6.  Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Nathan J Cherrington
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-07-03       Impact factor: 4.481

7.  Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis.

Authors:  Benjamin L Woolbright; Kenneth Dorko; Daniel J Antoine; Joanna I Clarke; Parviz Gholami; Feng Li; Sean C Kumer; Timothy M Schmitt; Jameson Forster; Fang Fan; Rosalind E Jenkins; B Kevin Park; Bruno Hagenbuch; Mojtaba Olyaee; Hartmut Jaeschke
Journal:  Toxicol Appl Pharmacol       Date:  2015-01-28       Impact factor: 4.219

8.  A comparison of gene expression in mouse liver and kidney in obstructive cholestasis utilizing high-density oligonucleotide microarray technology.

Authors:  Gerald U Denk; Shi-Ying Cai; Wen-Sheng Chen; Aiping Lin; Carol J Soroka; James L Boyer
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

Review 9.  Therapeutic targets for cholestatic liver injury.

Authors:  Benjamin L Woolbright; Hartmut Jaeschke
Journal:  Expert Opin Ther Targets       Date:  2015-10-19       Impact factor: 6.902

10.  Mouse organic solute transporter alpha deficiency enhances renal excretion of bile acids and attenuates cholestasis.

Authors:  Carol J Soroka; Albert Mennone; Lee R Hagey; Nazzareno Ballatori; James L Boyer
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.